PPARA and metabolic dysfunction-associated steatotic liver disease: More specifically, MASLD patients show global hepatic DNA hypomethylation in parallel with increasing hepatic inflammation grade, disease progression and increased hypermethylation of the promotor sequence of the nuclear receptor peroxisome proliferator-activated receptor-α (PPARα) gene (Francque et al., 2015; Li et al., 2018; Lai et al., 2020).